Y-mAbs Therapeutics announces new business units for Radiopharmaceuticals and DANYELZA, reporting preliminary revenues of $88 million for 2024. Y-mAbs Therapeutics, Inc. has announced strategic ...
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...
Y-mAbs is a commercial-stage biotech, and its one commercialized product, Danyelza, brought in $22.8 million for the second quarter and was responsible for all the company's net revenue. Those sales ...
During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of ...
(RTTNews) - Y-mAbs Therapeutics (YMAB) and Nobelpharma have entered into a license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of ...
Looking for the hottest segment of the biotech industry? Then take a look at monoclonal antibodies (mAbs). A new Datamonitor report projects 14 percent annual growth in the market for the antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results